ARTICLES
Paclitaxel: what schedule? What dose?
SG Arbuck
JCO Feb 1 1994: 233–236. [PDF]
Tumor immunity: will new keys unlock the door?
J Ritz
JCO Feb 1 1994: 237–238. [PDF]
In memoriam: Vera Peters
SB Sutcliffe, MK Gospodarowicz, and PJ Fitzpatrick
JCO Feb 1 1994: 239–240. [PDF]
	Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer
	JH Schiller, B Storer, K Tutsch, R Arzoomanian, D Alberti, C Feierabend, and D Spriggs
	JCO Feb 1 1994: 241–248. [Abstract] [PDF]
	Phase I trial of interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer
	MJ Kennedy, GB Vogelsang, RJ Jones, ER Farmer, AD Hess, V Altomonte, AM Huelskamp, and NE Davidson
	JCO Feb 1 1994: 249–257. [Abstract] [PDF]
	Aerosolized pentamidine for the prevention of Pneumocystis carinii pneumonia in children with cancer intolerant or allergic to trimethoprim/sulfamethoxazole
	MM Mustafa, A Pappo, J Cash, NJ Winick, and GR Buchanan
	JCO Feb 1 1994: 258–261. [Abstract] [PDF]
	Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia
	E Archimbaud, X Thomas, M Michallet, J Jaubert, J Troncy, D Guyotat, and D Fiere
	JCO Feb 1 1994: 262–267. [Abstract] [PDF]
	Prospective evaluation of internal adenopathy in a cohort of 43 patients with hairy cell leukemia
	D Hakimian, MS Tallman, DK Hogan, AW Rademaker, E Rose, and AA Nemcek, Jr
	JCO Feb 1 1994: 268–272. [Abstract] [PDF]
	Blasts in CSF with a normal cell count do not justify alteration of therapy for acute lymphoblastic leukemia in remission: a Childrens Cancer Group study
	DG Tubergen, JW Cullen, JM Boyett, GS Gilchrist, RT O'Brien, PF Coccia, and MJ Waskerwitz
	JCO Feb 1 1994: 273–278. [Abstract] [PDF]
	A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curie controlled clinical trial
	R Somers, P Carde, M Henry-Amar, M Tarayre, J Thomas, A Hagenbeek, M Monconduit, BE de Pauw, WP Breed, and L Verdonck
	JCO Feb 1 1994: 279–287. [Abstract] [PDF]
	Efficacy and toxicity of vinblastine, bleomycin, and methotrexate with involved-field radiotherapy in clinical stage IA and IIA Hodgkin's disease: a British National Lymphoma Investigation pilot study
	NP Bates, MV Williams, EM Bessell, G Vaughan Hudson, and B Vaughan Hudson
	JCO Feb 1 1994: 288–296. [Abstract] [PDF]
	Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study
	SJ Horning, A Adhikari, N Rizk, RT Hoppe, and RA Olshen
	JCO Feb 1 1994: 297–305. [Abstract] [PDF]
	Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease
	SC King, RJ Reiman, and LR Prosnitz
	JCO Feb 1 1994: 306–311. [Abstract] [PDF]
	Second cancer risk following Hodgkin's disease: a 20-year follow-up study
	FE van Leeuwen, WJ Klokman, A Hagenbeek, R Noyon, AW van den Belt-Dusebout, EH van Kerkhoff, P van Heerde, and R Somers
	JCO Feb 1 1994: 312–325. [Abstract] [PDF]
	Costimulation of cutaneous T-cell lymphoma cells by interleukin-7 and interleukin-2: potential autocrine or paracrine effectors in the Sezary syndrome
	FM Foss, Y Koc, MA Stetler-Stevenson, DT Nguyen, MC O'Brien, R Turner, and EA Sausville
	JCO Feb 1 1994: 326–335. [Abstract] [PDF]
	Vinorelbine as first-line chemotherapy for metastatic breast carcinoma
	A Romero, MG Rabinovich, CT Vallejo, JE Perez, R Rodriguez, MA Cuevas, M Machiavelli, JA Lacava, M Langhi, and L Romero Acuna
	JCO Feb 1 1994: 336–341. [Abstract] [PDF]
	Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation
	R Ghalie, CM Richman, SS Adler, MA Cobleigh, AD Korenblit, SD Manson, BC McLeod, SG Taylor, 4th, LA Valentino, and J Wolter
	JCO Feb 1 1994: 342–346. [Abstract] [PDF]
	Phase II study of topotecan in metastatic non-small-cell lung cancer
	TJ Lynch, Jr, L Kalish, G Strauss, A Elias, A Skarin, LN Shulman, M Posner, and E Frei, 3rd
	JCO Feb 1 1994: 347–352. [Abstract] [PDF]
	Phase II randomized trial comparing high-dose cisplatin with moderate- dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party
	JP Sculier, J Klastersky, V Giner, G Bureau, J Thiriaux, G Dabouis, A Efremidis, F Ries, MC Berchier, and R Sergysels
	JCO Feb 1 1994: 353–359. [Abstract] [PDF]
	Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients
	T Le Chevalier, D Brisgand, JY Douillard, JL Pujol, V Alberola, A Monnier, A Riviere, P Lianes, P Chomy, and S Cigolari
	JCO Feb 1 1994: 360–367. [Abstract] [PDF]
	After a treatment breakthrough: a comparison of trial and population- based data for advanced testicular cancer
	EJ Feuer, CM Frey, OW Brawley, SG Nayfield, JB Cunningham, NL Geller, GJ Bosl, and BS Kramer
	JCO Feb 1 1994: 368–377. [Abstract] [PDF]
	Cisplatin-based chemotherapy for ovarian germ cell malignancies: the Australian experience
	E Segelov, J Campbell, M Ng, M Tattersall, R Rome, K Free, N Hacker, and ML Friedlander
	JCO Feb 1 1994: 378–384. [Abstract] [PDF]
	Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer
	SG Taylor, 4th, AK Murthy, JM Vannetzel, P Colin, M Dray, DD Caldarelli, S Shott, E Vokes, JL Showel, and JC Hutchinson
	JCO Feb 1 1994: 385–395. [Abstract] [PDF]
	Sustained regression of a primary choroidal melanoma under the influence of a therapeutic melanoma vaccine
	MS Mitchell, PE Liggett, RL Green, J Kan-Mitchell, AL Murphree, G Dean, L Spears, and F Walonker
	JCO Feb 1 1994: 396–401. [Abstract] [PDF]
	Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma
	MS Mitchell, J Jakowatz, W Harel, G Dean, L Stevenson, WD Boswell, and S Groshen
	JCO Feb 1 1994: 402–411. [Abstract] [PDF]
	Controlled evaluation of three drug combination regimens versus fluorouracil alone for the therapy of advanced gastric cancer. North Central Cancer Treatment Group
	SA Cullinan, CG Moertel, HS Wieand, MJ O'Connell, MA Poon, JE Krook, JA Mailliard, and LK Tschetter
	JCO Feb 1 1994: 412–416. [Abstract] [PDF]
	Evaluation of the extent of lymphadenectomy in a randomized trial of Western- versus Japanese-type surgery in gastric cancer
	AM Bunt, J Hermans, MC Boon, CJ van de Velde, M Sasako, GJ Fleuren, and JA Bruijn
	JCO Feb 1 1994: 417–422. [Abstract] [PDF]
	Prognostic factors in osteosarcoma: a critical review
	AM Davis, RS Bell, and PJ Goodwin
	JCO Feb 1 1994: 423–431. [Abstract] [PDF]
The 24th annual David A. Karnofsky memorial lecture. Progress and prospects in cancer treatment: the Karnofsky legacy
IH Krakoff
JCO Feb 1 1994: 432–438. [PDF]
Paclitaxel and radiation-recall dermatitis
T Shenkier and K Gelmon
JCO Feb 1 1994: 439. [PDF]

SPECIAL DEPARTMENTS
ERRATUM
	Tumor-Cell DNA Content Predicts Outcome in Children and Adolescents With Clinical Group III Embryonal Rhabdomyosarcoma
	Alberto S. Pappo, William M. Crist, John Kuttesch, Susan Rowe, Richard A. Ashmun, Harold M. Maurer, William A. Newton, Lina Asmar, Xiaolong Luo, and David N. Shapiro for the Intergroup Rhabdomyosarcoma Study Committee of the Children's Cancer Group and the Pediatric Oncology Group
	JCO Feb 1 1994: 440. [Abstract] [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.